Veloxis receives tender offer from Asahi Kasei Group

Following a structured process, Veloxis Pharmaceuticals A/S ("Veloxis"), a company listed on Nasdaq Copenhagen, today entered into a transaction agreement with Asahi Kasei Pharma Denmark A/S ("Asahi Kasei") about Asahi Kasei's recommended conditional voluntary public offer to purchase all issued and outstanding shares and warrants in Veloxis. The board of directors of Veloxis has unanimously recommended that the shareholders accept the offer from Asahi Kasei. Plesner advised Veloxis in connection with the transaction.

The offer from Asahi Kasei corresponds to a total price of DKK 8.9bn, provided that all shares and warrants are sold.

The majority shareholders Lundbeckfonden and Novo Nordisk Fonden, the board of directors and the management team, which own more than 80% of the shares and warrants in Veloxis, have undertaken in advance to sell their shares as part of the offer.

Read more details about the tender offer and the related conditions in the public announcement from Veloxis


Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the US through Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, focusing primarily on the US market. Veloxis has developed Envarsus XR (tacrolimus extended-release tablets) based on the Veloxis' patented delivery technology, MeltDose®.

Plesner has been assisting Veloxis for many years, and we are very proud to have been given the opportunity to advise on this transformative transaction for Veloxis and its shareholders.

Our team on the case

Latest news on M&A and Capital Markets

Capital Markets